Table 5.
Differences of IL-6, TNF-α and APACHEII among three subgroups graded by the gap between eGFRcr and eGFRcysc.
| Median (IQR) | Group 1 | Group 2 | Group 3 | p Value (overall) | p Value (1 vs 2)* | p Value (1 vs 3) | p Value (2 vs 3) |
|---|---|---|---|---|---|---|---|
| IL6 (pg/ml)b | 30.21 (12.46–44.92) | 56.36 (28.43–203.98) | 97.72 (38.44–290.65) | 0.006 | 0.097 | 0.005 | 1.000 |
| TNFα (pg/ml)c | 7.6 (6.3–11.6) | 11.5 (7.3–16.7) | 13.1 (8.6–20.4) | 0.027 | 0.27 | 0.022 | 0.936 |
| APACHEII | 10 (8–13) | 14 (12–20) | 17 (10.5–20) | 0.001 | 0.009 | 0.001 | 1.000 |
| SOFA | 4 (1–5) | 6 (4–8) | 6.5 (4–8.75) | 0.002 | 0.006 | 0.005 | 1.000 |
| Death | 11 (57.9 %) | 19 (82.6 %) | 16 (66.7 %) | 0.205 | – | – | – |
| Glucocorticoid | 16 (84.2 %) | 17 (73.9 %) | 20 (83.3 %) | 0.632 | – | – | – |
aAll patients: n = 66, Group 1 = 19, Group 2 = 23, Group 3 = 24.
bAll patients: n = 56, Group 1 = 17, Group 2 = 18, Group 3 = 21.
cAll patients: n = 52, Group 1 = 15, Group 2 = 18, Group 3 = 19.
*Adjusted p-Value.
Groups I, II, and III represented patients with △eGFRcr-cysc %<25 %, 25 %–45 %, and >45 %, respectively.
△eGFRcr-cysc % was defined as △eGFRcr-cysc/mean of eGFRcr and eGFRcysc × 100 %. △eGFRcr-cysc %=